Publication date: Jul 21, 2024
During the COVID-19 pandemic, pancreatic surgery for pancreatic neuroendocrine tumors (PNETs) with surgical indications was postponed or canceled. Patients with PNET patients who underwent pancreatic surgery during the COVID-19 restriction period (3 years) were compared with a similar cohort of patients who underwent surgery in the previous 3 years. Data on patients’ characteristics, waiting time, and surgical and pathology outcomes were evaluated. During the study period, 370 patients received surgery for PNETs, 205 (55%) during the first period, and 165 (45%) during the pandemic. A lengthening of the waiting list (182 [IQR 100-357] vs. 60 [40-88] days, p
| Concepts | Keywords |
|---|---|
| 3years | COVID-19 |
| Canceled | Pancreatic neuroendocrine tumors |
| Pandemic | Pancreatic surgery |
| Surgery | Pancreatic tumors |
| SARS-CoV2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | neuroendocrine tumors |
| disease | MESH | COVID-19 pandemic |
| disease | VO | volume |
| disease | MESH | PNETs |
| disease | VO | time |
| disease | MESH | tumors |
Original Article
(Visited 1 times, 1 visits today)